Dr. Vande Casteele holds a Bachelor of Pharmaceutical Sciences and Masters in Drug Design and Development from the University of Leuven, Belgium. He performed research in the fields of molecular biology at the Institute of Medical Sciences, University of Aberdeen, Scotland, and in immunology at Sanquin, University of Amsterdam, the Netherlands. He obtained his Ph.D. in Pharmaceutical Sciences based on his research dissertation entitled “Optimizing anti-TNF therapy in inflammatory bowel disease patients, a step towards personalized dosing” at the University of Leuven, Belgium.
Dr. Vande Casteele currently holds an appointment as Assistant Professor of Medicine at the University of California San Diego, where he teaches a course on Biologics and Biosimilars Drug Development. His main research efforts focus on clinical pharmacology and translational medicine of small and large molecules used in the treatment of chronic inflammatory diseases, with an emphasis on characterizing pharmacokinetics and pharmacodynamics in relation to treatment outcomes in clinical practice and drug development.
Dr. Vande Casteele has published over 100 peer reviewed research articles and book chapters; has given over 30 invited lectures; and has received awards for his research contributions from distinguished professional organizations such as the European Crohn’s and Colitis Organization (ECCO), the American Gastroenterological Association (AGA), the Crohn’s and Colitis Foundation (CCF) and United European Gastroenterology (UEG) association.